ClinicalTrials.gg
CompletedNCT01769768Updated Dec 19, 2020

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

A Phase 1 interventional study of LDE225 and Wafarin in Advanced Solid Tumor, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive 800mg daily of LDE225 and two separate doses of either bupropion or warfarin.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Adults, Hh (Hedgehog) pathway inhibitor, LDE225, Warfarin, Bupropion, advanced solid tumor, drug-drug interaction, pharmacokinetic
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults
  • Patients with cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor which has progressed despite standard therapy, or for which no standard therapy exists or patients with locally advanced or basal cell carcinoma who are not amendable or eligible for standard therapy.
  • Protocol-defined renal , liver and bone marrow function

Exclusion criteria

Exclusion Criteria:

  • CNS (Central Nervous System) tumors as well as history of
  • Systemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies).
  • Radiation therapy within 4 weeks before first dose
  • agents within 4 weeks before start of study therapy
  • Patients with known allergy/ to warfarin or bupropion and/or related compounds
  • Patients with a history of/or active bleeding disorders
  • Patients receiving treatment with vitamin K, Coumadin or other agents containing warfarin and heparin. Heparin flush to maintain patency of a central venous access device is allowed.
  • Patients receiving treatment with bupropion.
  • Patients who have neuromuscular disorders that are associated with elevated CK (Creatine phosphokinase) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • Known diagnosis of (HIV), or C (testing is not mandatory for study entry)
  • Patients currently receiving systemic

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    LDE225+Warfarin

    At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.

    Drug: LDE225 · Drug: Wafarin

  • Experimental
    LDE225+Bupropion

    At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group

    Drug: LDE225 · Drug: Bupropion

Interventions

  • DrugLDE225

    LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.

  • DrugWafarin

    15 mg single dose of warfarin (oral tablet) will be given to patients.

  • 75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) parameter AUClast for S- and R-warfarin

    Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

  2. PK parameter AUClast for bupropion

    Pharmacokinetics bupropion : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

  3. PK parameter AUCinf for bupropion

    Pharmacokinetics of bupropion : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

  4. PK parameter AUCinf for S- and R-warfarin

    Pharmacokinetics of warfarin and bupropion : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

  5. PK parameter Cmax for S- and R-warfarin

    Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

  6. PK parameters Cmax for bupropion

    Pharmacokinetics of Bupropion : Maximum observed plasma concentration after drug administration

    Time frame: 7 days

Secondary outcomes

  1. effects of LDE225 on the pharmacodynamic activity of warfarin

    INR parameter (International Normalized Ratio) will be assessed to evaluate the pharmacodynamic effect of warfarin.

    Time frame: 7 days

  2. safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin

    safety laboratory parameters, adverse event reports, changes in vital signs, changes in physical examination parameters

    Time frame: 28 days cycles

  3. evaluate the preliminary evidence of anti-tumor activity of LDE225 in patients with advanced solid tumors

    CT or MRI imaging parameters to determine the objective response rate according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)

    Time frame: every other cycle

  4. assess the effect of LDE225 treatment on cardiac function

    ECGs will be performed to determine the effect of LDE on the cardiac function.

    Time frame: screening, cycle 4 and EOT

  5. effects of LDE225 on the pharmacodynamic activity of warfarin

    PT (Prothrombin time) parameter will be assessed to evaluate the pharmacodynamic effect of warfarin.

    Time frame: 7 days

  6. safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin

    safety laboratory parameters

    Time frame: 28 days cycles

  7. safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin

    adverse event reports

    Time frame: 28 days cycles

  8. safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin

    changes in vital signs

    Time frame: 28 days cycles

07

Study locations

13 sites
  • City of Hope National Medical Center Oncology
    Duarte, California 91010, United States
  • University of Kansas Medical Center CBYM338B2203
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital Dana-Farber Cancer Institute
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr
    Lebanon, New Hampshire 03756, United States
  • Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
    Hackensack, New Jersey 07601, United States
  • University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
  • University of Pittsburgh Cancer Institute UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina Dept.of Neurosciences/MS Ctr.
    Charleston, South Carolina 29425, United States
  • Cancer Centers of the Carolinas SC
    Greenville, South Carolina 29605, United States
  • Utah Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah / Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
08

References and documents

Publications

  • Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, Amaravadi RK, Vaishampayan U, LoRusso P, Shapiro GI, Olszanski AJ, Perez R, Gutierrez M, O'Rourke MA, Chung V, Lee JJ, Lewis LD. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2021 Mar;87(3):1291-1302. doi: 10.1111/bcp.14508. Epub 2020 Aug 20. PubMed 32736411 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2013
First posted
Jan 17, 2013
Start
Apr 2013
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01769768
Responsible party
Sponsor
First posted
Jan 17, 2013
Start date
Apr 2013
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Dec 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion